as 05-08-2025 4:00pm EST
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 131.3M | IPO Year: | 2020 |
Target Price: | $15.00 | AVG Volume (30 days): | 675.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.60 | EPS Growth: | N/A |
52 Week Low/High: | $1.31 - $8.23 | Next Earning Date: | 05-20-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
NKTX Breaking Stock News: Dive into NKTX Ticker-Specific Updates for Smart Investing
Zacks
25 days ago
GlobeNewswire
a month ago
BioPharma Dive
a month ago
MT Newswires
a month ago
GlobeNewswire
a month ago
Zacks
2 months ago
Zacks
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "NKTX Nkarta Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.